IMR Press / FBE / Volume 11 / Issue 1 / DOI: 10.2741/E846

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Beta2-adrenergic receptor variants in children and adolescents with bronchial asthma
Show Less
1 Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2 Ministry of Health and Population, Cairo, Egypt
3 Department of Pediatrics, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
4 Center for Information Sciences, Nile University, Giza, Egypt
5 Department of Biochemistry, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia
Send correspondence to: Manal S. Fawzy, Dept. of Medical Biochemistry, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia P.O. 1321, Tel: 00966- 583241944, Fax: 966146640705, E-mail:
Front. Biosci. (Elite Ed) 2019, 11(1), 61–78;
Published: 1 January 2019

The region encoding the N-terminal of human β2-adrenergic receptor gene (ADRB2) shows several polymorphisms. To this end, we studied change in susceptibility and/or response to therapy in 175 asthmatic children and adolescents by the two most common variants of the ADRB2 gene namely, rs1042713 (Gly16Arg) and rs1042714 (Gln27Glu). Although, the variants did not correlate with risk of development nor with the severity of the asthma, Gly16/Glu27 haplotype in homozygous individuals conferred protection against development of asthma and was associated with a lower frequency of dyspnea and sputum production. In contrast, the Arg16/Gln27 haplotype was associated with a better response to treatment. These findings show that the risk of development of asthma or response to treatment can be, respectively, deciphered by the detection of both rs1042713 and rs1042714 variants in ADRB2 gene.

Figure 1.
Back to top